The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil

被引:75
|
作者
Suzano, CES
Amaral, E
Sato, HK
Papaiordanou, PM
机构
[1] Univ Estadual Campinas, BR-13083881 Sao Paulo, Brazil
[2] Natl Immunizat Program, Dept Hlth, Sao Paulo, Brazil
关键词
yellow fever; immunization; vaccination; pregnancy;
D O I
10.1016/j.vaccine.2005.09.033
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: This Study describes the consequences of the inadvertent immunization of pregnant women during a mass vaccination campaign in the Campinas region of the state of Sao Paulo, Brazil, in February and March 2000. The study was carried Out by the Women's Comprehensive Healthcare Center (CAISM), at the State University of Campinas (UNICAMP). The objective of the Study was to evaluate the possible effects of the vaccine on pregnancy and conceptus, and to assess congenital infection resulting from immunization. Methods: Pregnant women who received the YF vaccine were identified at primary health clinics and referred to the study site, a public reference, high-risk clinic, serving 42 towns in a region with a population of 3,000,000. A 12-month serological follow-up for newborns (PRNT), and an examination to detect congenital abnormalities was offered to pregnant women, who signed a consent form. In a sub-sample of women who were delivered at the study site, additional exams were proposed: neonatal fontanel ultrasound, funduscopy, audiometry, neuro-pediatric follow-up until 12 months of age, and IgM detection at birth. Fifteen blood samples from placentas and umbilical cords were tested for PCR. Findings: A total of 480 pregnant, immunized women were identified, who had received the vaccine at a mean of 5.7 weeks (95% CI 5.2-6.2) of gestation. The great majority of women were unaware of their pregnancy at the time they were vaccinated, and only 46.7% were counseled to avoid immunization if pregnant. After a minimum 6-week interval, 98.2% pregnant women were IgG positive. A total of 19.6% of women reported mild adverse events (headache, fever or myalgia). No IgM antibodies were detected at birth and no placental or umbilical cord blood was positive according to PCR. The frequency of malformations (2.3% or 7/304 babies), miscarriages (2.5% or 11/441 pregnancies), stillbirths (0.7%) and premature delivery (7.8%) was similar to that found in the general population. At 12 months follow-up, 7% of samples were reactive to PRNT. However, after 12 months, only one child was seropositive. Interpretation: Contrary to a previous study, maternal seroconversion was very high when immunization was carried Out in early pregnancy. Vaccine applied during the first trimester does not appear to cause malformations, complications to the central nervous system, nor adverse perinatal results as represented by premature deliveries or perinatal deaths. The 12-month serological follow-up is inconclusive and should be extended to 24 months. Evaluation of the risk Of miscarriage was hindered by late presentation at the study clinic. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1421 / 1426
页数:6
相关论文
共 10 条
  • [1] Yellow Fever Vaccine-Related Neurotropic Disease in Brazil Following Immunization with 17DD
    Gandolfi, Flora de Andrade
    Estofolete, Cassia Fernanda
    Wakai, Marcia Catelan
    Negri, Andreia Francesli
    Barcelos, Michela Dias
    Vasilakis, Nikos
    Nogueira, Mauricio Lacerda
    [J]. VACCINES, 2023, 11 (02)
  • [2] Description of a Prospective 17DD Yellow Fever Vaccine Cohort in Recife, Brazil
    de Melo, Andrea Barbosa
    da Silva, Maria da Paz C.
    Magalhaes, Maria Cecilia F.
    Vega Gonzales Gil, Laura Helena
    Freese de Carvalho, Eduardo M.
    Braga-Neto, Ulisses M.
    Bertani, Giovani Rota
    Marques, Ernesto T. A., Jr.
    Cordeiro, Marli Tenorio
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2011, 85 (04): : 739 - 747
  • [3] Isolation and characterization of wild type yellow fever virus in cases temporally associated with 17DD vaccination during an outbreak of yellow fever in Brazil
    de Filippis, AM
    Nogueira, RMR
    Jabor, AV
    Schatzmayr, HG
    Oliveira, JC
    Dinis, SCD
    Galler, R
    [J]. VACCINE, 2004, 22 (9-10) : 1073 - 1078
  • [4] EFFECTS AND SAFETY OF THE YELLOW FEVER VACCINE 17DD IN PATIENTS WITH IMMUNOMEDIATED RHEUMATIC DISEASES
    Bica, Blanca
    Da Silva, Lucas Peixoto
    Pileggi, Gecilmara Salviato
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 2059 - 2060
  • [5] Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases
    Vasconcelos, PFC
    Luna, EJ
    Galler, R
    Silva, LJ
    Coimbra, TL
    Barros, VLRS
    Monath, TP
    Rodigues, SG
    Laval, C
    Costa, ZG
    Vilela, MFG
    Santos, CLS
    Papaiordanou, CMO
    Alves, VAF
    Andrade, LD
    Sato, HK
    Rosa, EST
    Froguas, GB
    Lacava, E
    Almeida, LMR
    Cruz, ACR
    Rocco, IM
    Santos, RTM
    Oliva, OFP
    [J]. LANCET, 2001, 358 (9276): : 91 - 97
  • [6] Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil
    Galler, R
    Pugachev, KV
    Santos, CLS
    Ocran, SW
    Jabor, AV
    Rodrigues, SG
    Marchevsky, RS
    Freire, MS
    Almeida, LFC
    Cruz, ACR
    Yamamura, AMY
    Rocco, IM
    da Rosa, EST
    Souza, LTM
    Vasconcelos, PFC
    Guirakhoo, F
    Monath, TP
    [J]. VIROLOGY, 2001, 290 (02) : 309 - 319
  • [7] 17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil
    Campi-Azevedo, Ana Carolina
    Peruhype-Magalhaes, Vanessa
    Grazziela Coelho-dos-Reis, Jordana
    Antonelli, Lis Ribeiro
    Costa-Pereira, Christiane
    Speziali, Elaine
    Reis, Laise Rodrigues
    Lemos, Jandira Aparecida
    Leite Ribeiro, Jose Geraldo
    Bastos Camacho, Luiz Antonio
    de Sousa Maia, Maria de Lourdes
    Barbosa de Lima, Sheila Maria
    Simoes, Marisol
    Martins, Reinaldo de Menezes
    Homma, Akira
    Cota Malaquias, Luiz Cosme
    Tauil, Pedro Luiz
    Costa Vasconcelos, Pedro Fernando
    Martins Romano, Alessandro Pecego
    Domingues, Carla Magda
    Teixeira-Carvalho, Andrea
    Martins-Filho, Olindo Assis
    [J]. EMERGING INFECTIOUS DISEASES, 2019, 25 (08) : 1511 - 1521
  • [8] Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases (vol 358, pg 91, 2001)
    Vasconcelos, P
    [J]. LANCET, 2001, 358 (9278): : 336 - 336
  • [9] Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?
    Martins, M. A.
    Silva, M. L.
    Marciano, A. P. V.
    Peruhype-Magalhaes, V.
    Eloi-Santos, S. M.
    Ribeiro, J. G. L.
    Correa-Oliveira, R.
    Homma, A.
    Kroon, E. G.
    Teixeira-Carvalho, A.
    Martins-Filho, O. A.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2007, 148 (01): : 90 - 100
  • [10] Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: Implications for the Brazilian National Immunization Program
    Bastos Camacho, Luiz Antonio
    da Silva Freire, Marcos
    da Luz Fernandes Leal, Maria
    Souza Maia, Maria De Lourdes
    Martins, Reinaldo Menezes
    Yamamoto Yoshida, Anna Maia
    Sato, Helena Keico
    Fernandes, Guilherme Cortes
    Perez de Castro, Ivone
    Lemos, Jandira Campos
    Barros, Eugenio Martins
    Igushi, Takumi
    Leitdo, Marcia Borges
    Batista, Maristela
    da Conceicao Barros, Maria
    Sao Paulo, Elisabete Paganini
    Nascimento, Marileide
    da Silva, Nilce
    Baran, Meri
    Pernambuco, Eduardo
    Leal Costa, Antonio Jose
    [J]. VACCINE, 2007, 25 (16) : 3118 - 3123